FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL | | | | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | | | |
| Estimated average burden | | | | | | | | | | |
| hours ner resnonse. | 0.5 | | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

| | | | or occaon co(n) or the investment company rice or 1540 | | | | | | | |
|--|-------------------------------------|----|--|---|--|---|--|--|--|--|
| 1. Name and Addres Landry Rober | ss of Reporting Perso $\frac{1}{2}$ | n* | 2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [REGN] | (Check | tionship of Reporting Pers all applicable) Director Officer (give title | son(s) to Issuer 10% Owner Other (specify | | | | |
| (Last) 777 OLD SAW I | | | 3. Date of Earliest Transaction (Month/Day/Year) 06/22/2020 | X | below) EVP Finance | below) | | | | |
| (Street) TARRYTOWN (City) | NY 10591 (State) (Zip) | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | | |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | |

| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | |
|--|--|---|---|---|---------------------------|---|---|---|---|----------------------|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | i (A) or : 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership | | |
| | | | Code | v | Amount | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | | (Instr. 4) |
| Common Stock | 06/22/2020 | | M ⁽¹⁾ | | 8,900 | A | \$555.67 | 33,273 | D | |
| Common Stock | 06/22/2020 | | F ⁽¹⁾ | | 8,388 | D | \$626.19 | 24,885 | D | |
| Common Stock | 06/23/2020 | | S ⁽¹⁾ | | 40 | D | \$624.65 | 24,845 | D | |
| Common Stock | 06/23/2020 | | S ⁽¹⁾ | | 56 | D | \$626.56(2) | 24,789 | D | |
| Common Stock | 06/23/2020 | | S ⁽¹⁾ | | 39 | D | \$628.64 | 24,750 | D | |
| Common Stock | 06/23/2020 | | S ⁽¹⁾ | | 82 | D | \$630.84 | 24,668 | D | |
| Common Stock | 06/23/2020 | | S ⁽¹⁾ | | 78 | D | \$631.25 ⁽³⁾ | 24,590 | D | |
| Common Stock | 06/23/2020 | | S ⁽¹⁾ | | 82 | D | \$633.56(4) | 24,508 | D | |
| Common Stock | 06/23/2020 | | S ⁽¹⁾ | | 89 | D | \$634.63(5) | 24,419 | D | |
| Common Stock | 06/23/2020 | | S ⁽¹⁾ | | 46 | D | \$635.24 | 24,373 | D | |
| Common Stock | | | | | | | | 200 | I | By 401(k) Plan |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | of | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---|---|--|---|------------------------------|---|-----|-------|--|--------------------|--|--|---|--|--|--|
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| Non- Qualified Stock Option (right to buy) | \$555.67 | 06/22/2020 | | M ⁽¹⁾ | | | 8,900 | (6) | 12/16/2025 | Common Stock | 8,900 | \$0.0 | 20,000 | D | |

Explanation of Responses:

- $1.\ Disposition/acquisition\ made\ pursuant\ to\ a\ plan\ intended\ to\ comply\ with\ Rule\ 10b5-1(c).$
- 2. Represents volume-weighted average price of sales of 56 shares of Company stock on June 23, 2020 at prices ranging from \$626.49 to \$626.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 23, 2020 at each separate price
- 3. Represents volume-weighted average price of sales of 78 shares of Company stock on June 23, 2020 at prices ranging from \$631.19 to \$631.33. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 23, 2020 at each separate price.
- 4. Represents volume-weighted average price of sales of 82 shares of Company stock on June 23, 2020 at prices ranging from \$633.40 to \$633.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 23, 2020 at each separate price.
- 5. Represents volume-weighted average price of sales of 89 shares of Company stock on June 23, 2020 at prices ranging from \$634.38 to \$634.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 23, 2020 at each separate price.
- 6. The stock option award vests in four equal annual installments, commencing one year after the date of grant.

/s/**Robert E. Landry

06/24/2020

** Signature of Reporting Person

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.